IPO Boutique Research, Color & More Information for Subscribers
This content is restricted to IPO Boutique Subscribers Username or E-mail: Become a Subscriber Disclaimer IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual[…]
This content is restricted to IPO Boutique Subscribers Username or E-mail: Become a Subscriber Disclaimer IPO Boutique aggregates information on public companies and private companies, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: RedHill Biopharma Ltd. Symbol: RDHL Price: Last trade $10.81 Description: No re-offer range available Trade Date: 12/21 Shares: TBD Underwriter(s)Roth Capital[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: RedHill Biopharma Ltd. Symbol: RDHL Price: Last trade $11.80 Description: No re-offer range available Trade Date: 11/2 Shares: TBD Underwriter(s)Roth Capital[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. Company: Digital Realty Trust Symbol: DLR Price: Last trade $68.42 Trade Date: 7/15 Shares: 10.5 million Underwriter(s) BofA Merrill Lynch, Morgan Stanley,[…]
IPOBoutique.Com rates secondary offerings to hit the tape with a ‘BUY’, ‘NEUTRAL’ or ‘AVOID’ rating. Senior Managing Partner Scott Sweet maintains a track record for all secondary’s he’s issued with a ‘BUY’ rating. To subscribe to his secondary ratings, click here. Company: Idera Pharmaceuticals